The Ripple Effect on Medical Devices: Bariatric Surgery Declines Amid GLP-1 Surge

The rapid, population-level adoption of GLP-1 receptor agonists is reshaping the medical device and surgical landscape. Specifically, metabolic bariatric surgery—historically the gold standard for durable weight loss—is experiencing a measurable decline as patients opt for pharmacological management.

Mass General Brigham Study Quantifies the Shift

A collaborative study by researchers at Brigham and Women’s Hospital, the Harvard T.H. Chan School of Public Health, and the Brown School of Public Health (published in JAMA Network Open) analyzed national medical insurance claims from over 17 million privately insured adults to evaluate the trade-offs between surgical and pharmacological weight management.

• GLP-1 Use Doubled: Between the last six months of 2022 and the last six months of 2023, the use of GLP-1 receptor agonists as anti-obesity medications increased by 105.7% (climbing from 2.16 to 4.43 patients per 1,000 patients).
• Surgical Volume Decline: During the exact same period, rates of metabolic bariatric surgery dropped by 8.7% (from 0.23 to 0.21 patients per 1,000 patients).
• Under-Treatment Remains High: Despite the massive surge in GLP-1 prescriptions, less than 1% of the privately insured sample with obesity actually received either form of treatment (0.5% received GLP-1s and 0.01% underwent surgery), indicating a vast, underserved addressable market.

Verbatim Evidence

"Researchers documented a 105.7% increase in patients prescribed GLP-1 drugs between 2022 and 2023, and an 8.7% decrease in patients undergoing bariatric surgery... Only 0.51% of patients with obesity in the study population received either GLP-1 drugs or surgery, suggesting that many more patients could be receiving treatment." — Mass General Brigham News Release: Oct 25, 2024

"With the national decline in utilization of metabolic bariatric surgery and potential closure of bariatric surgery programs, there is a concern that access to comprehensive multidisciplinary treatment of obesity involving pharmacologic, endoscopic, or surgical interventions may become more limited." — Mass General Brigham News Release: Oct 25, 2024

Investor Implications

• Surgical Device Headwinds: Medical device manufacturers specializing in bariatric surgical equipment (such as staplers, gastric bands, and specialized laparoscopic tools) face ongoing headwinds as surgical volumes contract. This trend may lead to the consolidation or closure of specialized bariatric surgery centers.
• A "Hybrid" Future: Leading bariatric surgeons and medical societies are increasingly advocating for a "hybrid" model of care, combining GLP-1 medications with surgery to manage post-surgical weight regain or to optimize patients pre-operatively.
• Massive Untapped Market: For long-term investors, the fact that less than 6% of eligible patients with obesity receive any medical or surgical intervention highlights that the market is not yet zero-sum. The long-term growth runway for both pharmaceuticals and advanced medical devices remains exceptionally long.